Market Closed -
OTC Markets
12:55:38 26/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.21
USD
|
+22.81%
|
|
-16.03%
|
-68.52%
|
Fiscal Period: December |
2023
|
---|
Capitalization
1 |
7.935
|
Enterprise Value (EV)
1 |
11.37
|
P/E ratio
|
-0.08
x
|
Yield
|
-
|
Capitalization / Revenue
|
610
x
|
EV / Revenue
|
875
x
|
EV / EBITDA
|
-0.33
x
|
EV / FCF
|
-35,03,334
x
|
FCF Yield
|
-0%
|
Price to Book
|
-0.32
x
|
Nbr of stocks (in thousands)
|
11,897
|
Reference price
2 |
0.6670
|
Announcement Date
|
16/04/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net sales
1 |
0.692
|
0.013
|
EBITDA
1 |
-37.34
|
-34.9
|
EBIT
1 |
-37.5
|
-35.27
|
Operating Margin
|
-5,419.51%
|
-2,71,276.92%
|
Earnings before Tax (EBT)
1 |
-37.43
|
-51.98
|
Net income
1 |
-38.01
|
-48.07
|
Net margin
|
-5,493.21%
|
-3,69,784.62%
|
EPS
2 |
-13.13
|
-7.987
|
Free Cash Flow
|
-
|
-3.245
|
FCF margin
|
-
|
-24,963.46%
|
FCF Conversion (EBITDA)
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
16/04/24
|
16/04/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net Debt
1 |
-
|
3.43
|
Net Cash position
1 |
0.66
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.0984
x
|
Free Cash Flow
|
-
|
-3.25
|
ROE (net income / shareholders' equity)
|
-
|
377%
|
ROA (Net income/ Total Assets)
|
-
|
-181%
|
Assets
1 |
-
|
26.55
|
Book Value Per Share
2 |
-0.3800
|
-2.050
|
Cash Flow per Share
2 |
0.8300
|
0.4100
|
Capex
|
-
|
-
|
Capex / Sales
|
-
|
-
|
Announcement Date
|
16/04/24
|
16/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -68.52% | 89.53L | | +38.36% | 5.27TCr | | +36.73% | 3.9TCr | | -8.63% | 3.85TCr | | +25.46% | 3.04TCr | | -11.17% | 2.64TCr | | +11.44% | 2.61TCr | | +45.09% | 1.42TCr | | +32.93% | 1.26TCr | | -5.30% | 1.15TCr |
Other Biotechnology & Medical Research
|